SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 208.29-0.3%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (13193)1/10/1998 8:35:00 PM
From: Andrew H  Read Replies (3) of 32384
 
Henry, its very difficult getting through on SI. Is LGND 1268 the same as ALRT 268 as described in the annual report?

In regard to Targretin, I checked the latest cheat sheet and didn't find the indication listed, which I found surprising. Given the results in rats that showed Targretin equal or superior to Tamoxifen (which is the prsently the leading treatment), one would think that LGND would be well into P2s already. As with diabetes, P1s would probably not be necessary. Breast cancer is a real killer and a large market as well, so one would think there would be plenty of support for trials and perhaps they would even be funded by the NCI, given the preventative nature of Targretin.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News